A lot of investors seem to think that all a company has to do to succeed in health care is develop a better therapy and the patients and docs will magically appeal. Unfortunately, that's never been true - strong clinical data and large under-served patient populations certainly help make a good story, but strong marketing often matters quite a bit.
That seems particularly relevant in the case of micro-cap med-tech company Uroplasty (UPI). The company's Urgent PC neurostimulation system for overactive bladder really does seem like a viable alternative in the $3 billion market it serves, but adoption has been slow and the company still has a lot yet to prove.
Read the full article here:
Can Uroplasty Drive Adoption Of Its Better Mousetrap?
No comments:
Post a Comment